Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., Newlands, E. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1995
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2034149/
https://ncbi.nlm.nih.gov/pubmed/7599050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados